BOOK
Sjogren’s Disease, An Issue of Rheumatic Disease Clinics of North America, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of Rheumatic Disease Clinics is devoted to Sjogren's Disease. The articles will include everything from the Use of Biologics, Autoantibodies, and Genetics, to Proteomics of Saliva/Tears, Parotid Biopsy, Use of Ultrasound, and many more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Sjogren's Disease\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Sjogren Disease\r | vii | ||
| Preface: Sjögren Syndrome in the Twenty-First Century\r | vii | ||
| Use of Biologics in Sjögren’s Syndrome\r | vii | ||
| Autoantibodies in Sjögren’s Syndrome\r | vii | ||
| Genetics in Sjögren Syndrome\r | vii | ||
| The Proteomics of Saliva in Sjögren’s Syndrome\r | viii | ||
| Polyautoimmunity in Sjögren Syndrome\r | viii | ||
| Salivary Gland Pathology in Sjögren’s Syndrome\r | viii | ||
| Parotid Gland Biopsy, the Alternative Way to Diagnose Sjögren Syndrome\r | viii | ||
| Major Salivary Gland Ultrasonography in the Diagnosis of Sjögren’s Syndrome: A Place in the Diagnostic Criteria?\r | ix | ||
| Sjögren Syndrome: Why Do Clinical Trials Fail?\r | ix | ||
| New Treatment Guidelines for Sjögren's Disease\r | ix | ||
| RHEUMATIC DISEASE CLINICS\rOF NORTH AMERICA\r | x | ||
| FORTHCOMING ISSUES | x | ||
| November 2016 | x | ||
| February 2017 | x | ||
| May 2017 | x | ||
| RECENT ISSUES | x | ||
| May 2016 | x | ||
| February 2016 | x | ||
| November 2015 | x | ||
| Foreword: Sjogren's Disease\r | xi | ||
| Preface: Sjögren Syndrome in the Twenty-First Century\r | xiii | ||
| Use of Biologics in Sjögren's Syndrome | 407 | ||
| Key points | 407 | ||
| INTRODUCTION | 407 | ||
| WHAT ARE THE THERAPEUTIC OBJECTIVES IN PRIMARY SJÖGREN SYNDROME? | 408 | ||
| B-cell Target Therapies | 408 | ||
| B cell as a central actor of primary Sjögren syndrome pathogeny | 408 | ||
| Rituximab | 408 | ||
| Registries and open-labeled studies | 408 | ||
| Randomized controlled studies | 409 | ||
| Epratuzumab | 409 | ||
| B-cell activating factor of the tumor necrosis factor family inhibition | 411 | ||
| TUMOR NECROSIS FACTOR BLOCKERS | 411 | ||
| NEW TARGETS AND FUTURE HOPES | 411 | ||
| Novel Strategies to Target B Cells | 411 | ||
| Germinal Centerlike Structures: A Promising Target | 413 | ||
| Lymphotoxin | 413 | ||
| CD4 T follicular helper cells | 413 | ||
| T-Cell Costimulation | 414 | ||
| Type I Interferons | 414 | ||
| RESEARCH AGENDA | 414 | ||
| REFERENCES | 414 | ||
| Autoantibodies in Sjögren’s Syndrome | 419 | ||
| Key points | 419 | ||
| INTRODUCTION | 419 | ||
| AUTOANTIBODIES PRECEDE DISEASE | 420 | ||
| SJÖGREN'S SYNDROME B (SSB) | 421 | ||
| ANTI-RO/SSA IN NEONATAL LUPUS | 422 | ||
| RHEUMATOID FACTOR | 424 | ||
| ANTI-MUSCARINIC RECEPTOR AUTOANTIBODIES | 424 | ||
| ANTI-CENTROMERE ANTIBODY | 425 | ||
| OTHER AUTOANTIBODIES IN SJÖGREN SYNDROME | 426 | ||
| NOVEL ANTIBODIES | 427 | ||
| SUMMARY | 428 | ||
| REFERENCES | 428 | ||
| Genetics in Sjögren Syndrome | 435 | ||
| Key points | 435 | ||
| ANTIGEN PRESENTATION | 436 | ||
| THE INNATE IMMUNE RESPONSE | 437 | ||
| LYMPHOCYTE REGULATION AND ACTIVATION | 439 | ||
| OTHER GENES WITH SUGGESTIVE ASSOCIATIONS IN SJÖGREN SYNDROME | 440 | ||
| REFERENCES | 442 | ||
| The Proteomics of Saliva in Sjögren's Syndrome | 449 | ||
| Key points | 449 | ||
| INTRODUCTION | 449 | ||
| SALIVA: PRODUCTION AND SECRETION | 450 | ||
| COMPOSITION | 450 | ||
| FUNCTION | 451 | ||
| SALIVA FOR BIOMARKER DISCOVERY IN PRIMARY SJÖGREN SYNDROME | 451 | ||
| An Attractive Biofluid | 451 | ||
| Challenges | 451 | ||
| Immunologic Proteins in Saliva | 451 | ||
| Salivary Proteomics for Primary Sjögren Syndrome Diagnosis | 452 | ||
| Prognostic Biomarkers of Lymphoma in Primary Sjögren Syndrome | 453 | ||
| SUMMARY | 453 | ||
| REFERENCES | 454 | ||
| Polyautoimmunity in Sjögren Syndrome | 457 | ||
| Key points | 457 | ||
| INTRODUCTION | 457 | ||
| Historical Perspective | 459 | ||
| Polyautoimmunity or Overlap Syndrome? | 459 | ||
| POLYAUTOIMMUNITY IN SJÖGREN SYNDROME | 461 | ||
| Sjögren Syndrome and Autoimmune Hepatitis | 461 | ||
| Sjögren Syndrome and Rheumatoid Arthritis | 464 | ||
| Sjögren Syndrome and Systemic Lupus Erythematosus | 464 | ||
| Sjögren Syndrome and Systemic Sclerosis | 464 | ||
| Sjögren Syndrome and Hepatic Autoimmune Diseases | 465 | ||
| SEVERITY OF POLYAUTOIMMUNITY | 465 | ||
| FACTORS ASSOCIATED WITH POLYAUTOIMMUNITY IN SJÖGREN SYNDROME | 466 | ||
| AUTOIMMUNE TAUTOLOGY AND SJÖGREN SYNDROME | 466 | ||
| FUTURE CONSIDERATIONS | 467 | ||
| SUMMARY | 468 | ||
| REFERENCES | 468 | ||
| Salivary Gland Pathology in Sjögren's Syndrome | 473 | ||
| Key points | 473 | ||
| INTRODUCTION | 473 | ||
| SALIVARY GLAND EPITHELIAL CELLS AND ACTIVATION OF THE INTERFERON TYPE I PATHWAY | 474 | ||
| T LYMPHOCYTES | 475 | ||
| B CELLS AND LYMPHONEOGENESIS | 476 | ||
| TISSUE DAMAGE/FIBROSIS AND DRYNESS | 478 | ||
| SUMMARY | 478 | ||
| REFERENCES | 478 | ||
| Parotid Gland Biopsy, the Alternative Way to Diagnose Sjögren Syndrome | 485 | ||
| Key points | 485 | ||
| INTRODUCTION | 485 | ||
| MINOR SALIVARY GLAND BIOPSY | 486 | ||
| Surgical Considerations | 486 | ||
| Histologic Grading | 487 | ||
| Complications | 487 | ||
| PAROTID GLAND BIOPSY | 487 | ||
| Surgical Considerations | 487 | ||
| Histologic Grading | 491 | ||
| Complications | 492 | ||
| SUITABILITY OF SALIVARY GLAND BIOPSIES | 492 | ||
| Diagnostic | 492 | ||
| Disease Progression | 493 | ||
| Treatment Evaluation Purposes | 493 | ||
| SALIVARY GLAND BIOPSIES AND LYMPHOMAS | 495 | ||
| SUMMARY | 495 | ||
| REFERENCES | 496 | ||
| Major Salivary Gland Ultrasonography in the Diagnosis of Sjögren’s Syndrome | 501 | ||
| Key points | 501 | ||
| INTRODUCTION | 501 | ||
| MODALITIES FOR SALIVARY GLAND IMAGING | 503 | ||
| Ultrasonography and Sialography | 503 | ||
| Ultrasonography and Sialoscintigraphy | 505 | ||
| NOVEL PERSPECTIVES | 506 | ||
| Gray Scale and Color/Power Doppler | 506 | ||
| Contrast-Enhanced Ultrasonography | 507 | ||
| Sonoelastography | 507 | ||
| DIAGNOSTIC APPLICATIONS AND PROGNOSTIC VALUE | 508 | ||
| Scoring Systems | 508 | ||
| Juvenile Sjögren’s Syndrome | 512 | ||
| SUMMARY AND DISCUSSION | 513 | ||
| REFERENCES | 514 | ||
| Sjögren Syndrome | 519 | ||
| Key points | 519 | ||
| INTRODUCTION | 519 | ||
| BACKGROUND | 520 | ||
| REASONS FOR FAILURE OF TRIALS OF BIOLOGICS IN SJÖGREN SYNDROME TRIALS | 520 | ||
| MAJOR PROBLEM IN ENROLLING SJÖGREN SYNDROME PATIENTS WITH EXTRAGLANDULAR MANIFESTATIONS: MANY OF THE SICKEST SJÖGREN SYNDRO ... | 523 | ||
| A PRACTICAL METHOD TO IMPROVE DIAGNOSIS OF SJÖGREN SYNDROME PATIENTS | 524 | ||
| THE MECHANISMS OF FATIGUE | 524 | ||
| THE FUNCTIONAL CIRCUIT | 525 | ||
| SUMMARY | 526 | ||
| REFERENCES | 527 | ||
| APPENDIX 1 | 530 | ||
| New Treatment Guidelines for Sjögren's Disease | 531 | ||
| Key points | 531 | ||
| INTRODUCTION | 532 | ||
| HIGH BURDEN OF ILLNESS | 532 | ||
| GUIDELINES DEVELOPMENT | 532 | ||
| DEFINING CLINICAL ISSUES | 533 | ||
| TOPIC REVIEW AND THE DELPHI CONSENSUS PROCESS | 534 | ||
| Guidelines for Oral Management | 534 | ||
| Index | 553 |